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Background/aim: To elucidate how the combination of fatty liver and increased serum gamma-glutamyl transpeptidase (GGT) levels
influences atherosclerotic plaque development in apparently healthy people.
Materials and methods: The study population included people who had received an annual health checkup for more than 7 years and
had no evidence of carotid plaque at baseline. We investigated the risk factors for carotid plaque occurrence using the Cox proportional
hazards model.
Results: A total of 107 people (76 men and 31 women; median age, 49 years) were enrolled. At baseline, fatty liver and a serum GGT
level ≥50 U/L were observed in 13 and 38 people, respectively. During a median follow-up period of 13.3 years, carotid plaques appeared
in 34 people. Multivariate analysis revealed that the combination of fatty liver and a serum GGT level ≥50 U/L was the only significant
risk factor for carotid plaque occurrence (age- and sex-adjusted hazard ratio: 5.55; 95% confidence interval 1.70–18.14; P = 0.005).
Conclusion: The combination of fatty liver and increased serum GGT levels raises the risk for atherosclerotic plaque development in
apparently healthy people.
Key words: Fatty liver, serum gamma-glutamyl transpeptidase, carotid plaque, apparently healthy people

1. Introduction
Atherosclerosis is a key pathological mechanism underlying cardiovascular disease (CVD) [1]. Recent studies have
provided evidence of the pivotal role of gamma-glutamyl
transpeptidase (GGT) in atherosclerosis progression [2–
4]. Histochemical studies revealed the presence of GGT
activity in human coronary plaques [2,3]. Human carotid
plaques contain glutathione, cysteinyl-glycine, cysteine,
and low-density lipoprotein (LDL)/GGT complexes [4]. A
possible underlying mechanism of atherosclerotic plaque
development is as follows: elevated serum GGT levels may
augment GGT-lipoprotein complex entry into arterial
plaques, which can enhance GGT-mediated glutathione
degradation and thus increase the amount of cysteinylglycine in the plaques. Cysteinyl-glycine has the potential
to promote LDL oxidation by generating superoxide radicals via an iron reduction reaction and thus contributes
to atherosclerotic plaque development [5]. A recent largescale population-based study demonstrated that serum

GGT levels are a biomarker that can predict stroke risk [6].
Furthermore, many studies have suggested the positive association of fatty liver disease with atherosclerosis [7–9].
A metaanalysis showed a strong association between nonalcoholic fatty liver disease (NAFLD) and carotid intimamedia thickness and plaques [7]. Some studies have shown
that NAFLD induces atherosclerosis-associated factors,
including proinflammatory cytokines and coagulation factors [10,11]. Considering these data, we hypothesized that
the combination of fatty liver and increased serum GGT
levels may accelerate atherosclerotic plaque development.
We then performed a cross-sectional study to test this hypothesis. Although our study demonstrated a close relationship between these two conditions and carotid plaque
presence, the study design could not prove causality between them [12]. The aim of this longitudinal study was
to determine whether the combination of these conditions
raises the risk for atherosclerotic plaque development in
apparently healthy people.
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2. Materials and methods
2.1. Study subjects
This retrospective longitudinal study included people who
had received an annual health checkup for more than 7
years at our health evaluation center and had no evidence
of carotid plaque at baseline. The exclusion criteria were
as follows: a history of CVD; hepatitis B or C virus infection; and medications capable of influencing the course of
atherosclerosis, including antihypertensive agents, antidyslipidemic agents, antidiabetic agents, and antiplatelet/
anticoagulant agents. People who had any exclusion criteria through the end of this study were excluded. The study
period was between January 2001 and December 2016.
The study protocol was approved by the ethics committee
of Kanazawa Medical University (approval no. 144) and
was conducted in accordance with the Declaration of Helsinki. Written informed consent was waived by the ethics
committee.
2.2. Examinations
The physical examination included height, weight, and
blood pressure, which was measured using a mercury
sphygmomanometer. Hypertension was defined according to the Japanese Society of Hypertension guidelines
for managing hypertension: systolic blood pressure ≥140
mmHg or diastolic blood pressure ≥90 mmHg [13]. Laboratory tests included serum lipid levels, such as serum
triglyceride levels, measured using enzymatic color tests
(Kyowa Medex Co., Ltd., Tokyo, Japan); serum high-density lipoprotein (HDL) and LDL cholesterol levels, measured
using the direct method (Sekisui Medical Co., Ltd., Tokyo,
Japan); fasting blood glucose levels, assessed by the hexokinase method (Shino-Test Corporation, Tokyo, Japan);
serum glycated hemoglobin (HbA1c) levels, measured by
an enzymatic assay (Kyowa Medex Co., Ltd., Tokyo, Japan);
and serum hepatobiliary enzyme levels, such as serum aspartate aminotransferase (AST), alanine aminotransferase
(ALT), and GGT levels, measured using the Japan Society of Clinical Chemistry (JSCC) standardization method
(Kanto Chemical Co., Inc., Tokyo, Japan). Smoking status
was classified as follows: never smoked, past smoking, and
current smoking. The alcohol consumption questionnaire
assessed the number of drinking days/week over a period
of at least one year, and alcohol consumption was evaluated according to the number of standard drinks/drinking day (one standard drink is defined as 10 g of alcohol
in Japan). Thus, average daily alcohol consumption was
calculated as follows: (number of drinking days/week) ×
(alcohol consumption/drinking day)/7.
Carotid and abdominal ultrasound (US) examinations
were routinely performed in a health checkup at our
health evaluation center. Experienced ultrasonographers
who were blinded to the health checkup data of each

person performed these examinations. High-resolution
US machines (Aplio XG/500/80, Canon Medical Systems
Corporation, Tochigi, Japan) and an 8.4- or 9-MHz probe
were used for carotid US. Carotid plaques were defined
as intima-media thickness >1.5 mm in any portion of the
carotid arteries [14]. The same US machines and a 5-MHz
probe were used for abdominal US. The diagnosis of fatty
liver was made on the basis of increased echogenicity of
the liver parenchyma compared to the echogenicity of the
right renal cortex [15].
2.3. Statistical analysis
Continuous variables are expressed as the median (25th,
75th percentile). We calculated the cumulative incidence
rates of carotid plaque occurrence with the Kaplan–Meier
method and performed log-rank tests to evaluate the rate
differences. We investigated the risk factors for carotid
plaque occurrence using the Cox proportional hazards regression model. The following variables were potential risk
factors: age (years), sex, body mass index (BMI; kg/m2),
hypertension (absence/presence), serum triglyceride level
(mg/dL), serum HDL cholesterol level (mg/dL), serum
LDL cholesterol level (mg/dL), fasting blood glucose level
(mg/dL), serum HbA1c (%), serum GGT level (U/L), fatty
liver (absence/presence), smoking status (never smoked/
past and current smoking), and alcohol consumption (≤20
g/day/>20, <60 g/day/≥60 g/day). We created two statistical models. The first model used the variables described
above (model 1), and the second model used the following combinations of the presence or absence of fatty liver
and serum GGT levels (a mean value of 50 U/L was the
cut-off): nonfatty liver and a serum GGT level <50 U/L,
fatty liver and a serum GGT level <50 U/L, nonfatty liver
and a serum GGT level ≥50 U/L, and fatty liver and a serum GGT level ≥50 U/L (model 2). We performed a multivariate analysis using variables with P < 0.2, according
to a univariate analysis, and calculated the age- and sexadjusted hazard ratios of the variables, and P < 0.05 was
considered statistically significant. All statistical analyses
were performed using STATA version 13.1 (STATA Corp.,
College Station, TX, USA).
3. Results
3.1. Baseline characteristics of the cohort
A total of 599 people received a health checkup annually
for more than 7 years. However, 492 people received medications capable of influencing the course of atherosclerosis
before the study and/or during the study period. Thus, this
study enrolled 107 people (76 men and 31 women; median
age, 49 years). At baseline, fatty liver and a serum GGT
level ≥50 U/L were observed in 13 and 38 people, respectively (Table 1).
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Table 1. Baseline characteristics of the whole cohort (n = 107).

100

Age, years

49 (44, 55)

Sex, men/women

76/31

BMI, kg/m2

22.5 (21.1, 24.8)

Hypertension, no/yes

103/4

Triglyceride, mg/dL

104 (75, 159)

HDL cholesterol, mg/dL

56 (47, 67)

LDL cholesterol, mg/dL

121 (98, 141)

FBG, mg/dL

91 (86, 97)

HbA1c, %

5.5 (5.2, 5.8)

AST, U/L

22 (19, 26)

ALT, U/L

22 (16, 31)

GGT, U/L

31 (19, 72)

GGT ≥50 U/L, no/yes

69/38

Fatty liver, no/yes

94/13

Smoking, never/past/current

46/27/34

Drinking, <20/>20, <60/≥60, g/day

84/6/17

Continuous variables are expressed as medians (25th, 75th
percentile). BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; FBG: fasting blood
glucose; HbA1c: serum glycated hemoglobin; AST: aspartate
aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl transpeptidase.

3.2. Cumulative incidence rates of carotid plaque occurrence
All the enrolled participants received the carotid and abdominal US examinations annually. During a median
follow-up period of 13.3 years (range: 7.2 to 15.5 years),
carotid plaques emerged in 34 people (24 men and 10
women); the cumulative incidence rates were 10%, 23%,
and 40% at 5, 10, and 15 years, respectively (Figure 1).
There was no significant difference in the incidence rates
of carotid plaque between people with or without fatty liver (P = 0.38) (Figure 2). However, the incidence rates were
significantly higher in people with a serum GGT level ≥50
U/L than in those with a serum GGT level <50 U/L (P =
0.020) (Figure 3). When the subjects are divided into four
groups according to the presence or absence of fatty liver
and serum GGT levels, those with fatty liver and a serum
GGT level ≥50 U/L (n = 8) had the highest incidence rates,
followed by those with only a serum GGT level ≥50 U/L (n
= 30), those without the presence of either factor (n = 64),
and those with fatty liver only (n = 5) (P = 0.017); the rates
for these groups at 10 years were 62.5%, 34.3%, 14.5%, and
0%, respectively (Figure 4).
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Figure 1. Incidence rates of carotid plaque occurrence in the
whole cohort (n = 107).

3.3. Risk factors for carotid plaque occurrence (model 1)
We first performed a Cox proportional hazards regression
analysis using the variables in model 1. Univariate analysis
revealed that the variables with P < 0.2 were serum triglyceride level, serum HDL cholesterol level, serum LDL
cholesterol level, serum GGT level, and past and current
smoking. However, multivariate analysis identified no significant predictors (Table 2).
3.4. Risk factors for carotid plaque occurrence (model 2)
We next performed an analysis using the variables in model 2. Univariate analysis revealed that the variables with P <
0.2 were serum triglyceride level, serum HDL cholesterol
level, serum LDL cholesterol level, nonfatty liver and a serum GGT level ≥50 U/L, fatty liver and a serum GGT level
≥50 U/L, and past and current smoking. According to the
multivariate analysis, the combination of fatty liver and a
serum GGT level ≥50 U/L was the only significant risk factor for carotid plaque occurrence (age- and sex-adjusted
hazard ratio: 5.55; 95% confidence interval: 1.70–18.14; P
= 0.005) (Table 3).
4. Discussion
In the current study, we have demonstrated that the
combination of fatty liver and increased serum GGT levels
increases the risk for atherosclerotic plaque development
in apparently healthy people. Our previous cross-sectional
study found a close relationship between the combination
of these two conditions and the presence of carotid plaques
[12]. This longitudinal study clearly showed the causal
relationship between them. Because many studies have
demonstrated a close link between carotid atherosclerosis
and future CVD events, people with both conditions are
considered to be at high risk for CVD [16–18]. In clinical
practice, physicians should pay attention to such people,
urge them to receive a carotid US examination, and follow
them closely.
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Fatty liver (n = 13)

100

Rate (%)

Nonfatty liver (n = 94)

50

0
0

5

10

15

Time (years)

Patients at risk
Fatty liver

13

9

7

0

Nonfatty liver

94

86

61

14

Figure 2. Comparison of the incidence rates of carotid plaque occurrence between people
with and without fatty liver (P = 0.38).

Serum GGT level ≥ 50 U/L (n =69)

100

Rate (%)

Serum GGT level < 50 U/L (n = 38)

50

0
0

5

10

15

Time (years)

Patients at risk
Serum GGT level ≥ 50 U/L 69

64

49

9

Serum GGT level < 50 U/L 38

31

19

5

Figure 3. Comparison of the incidence rates of carotid plaque occurrence between two
groups divided according to serum GGT levels (P = 0.020).

The current study revealed a novel biomarker for predicting atherosclerotic plaque development in apparently
healthy people. In planning this study, we suspected that
it would be difficult to precisely estimate the impacts of
medications capable of influencing the course of atherosclerosis. Therefore, we excluded people who received such

medications in the past and would be taking them during
the study period. As a result, apparently healthy people
were enrolled as the study subjects. Many epidemiological
studies have reported risk factors for atherosclerosis development, including hypertension, dyslipidemia, diabetes
mellitus, obesity, and smoking [19]. Indeed, low serum
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Fatty liver and serum GGT level ≥ 50 U/L (n = 8)

100

Nonfatty liver and serum GGT level ≥ 50 U/L (n = 30)
Nonfatty liver and serum GGT level < 50 U/L (n = 64)

Rate (%)

Fatty liver and serum GGT level < 50 U/L (n =5)

50

0
0

5

10

15

Time (years)
Patients at risk
Fatty liver and serum GGT level ≥ 50 U/L

8

4

3

0

Nonfatty liver and serum GGT level ≥ 50 U/L

30

27

16

5

Nonfatty liver and serum GGT level < 50 U/L

64

59

45

9

Fatty liver and serum GGT level < 50 U/L

5

5

4

0

Figure 4. Comparison of the incidence rates of carotid plaque occurrence among four groups divided according to
the presence or absence of fatty liver and serum GGT levels (P = 0.017).

Table 2. Risk factors for carotid plaque occurrence (model 1).
Univariate analysis

Multivariate analysis

Variable

HR

95% CI

P-value HR

95% CI

P-value

Age, years

1.00

0.96–1.04

0.90

0.99

0.94–1.03

0.51

0.97

0.46–2.03

0.94

0.89

0.41–1.94

0.77

BMI, kg/m

1.08

0.96–1.21

0.22

Hypertension

0.75

0.10–5.50

0.78

Triglyceride, mg/dL

1.001 0.999–1.002 0.099

1.00

0.99–1.01

0.90

HDL, mg/dL

0.97

0.95–0.99

0.025

0.98

0.95–1.01

0.15

LDL, mg/dL

1.01

0.99–1.02

0.14

1.01

1.00–1.02

0.18

FBG, mg/dL

1.00

0.96–1.03

0.83

HbA1c, %

0.95

0.36–2.46

0.91

GGT, U/L

1.006 1.001– 1.012 0.021

Fatty liver

1.53

Never smoked

1.00

Past and current smoking

2.56

Drinking ≤20 g/day

1.00

Drinking >20, <60 g/day
Drinking ≥60 g/day

Men
2

0.59–3.97

0.38

1.19–5.50

0.016

1.09

0.26–4.62

0.90

1.52

0.66–3.51

0.33

1.005 0.999–1.011 0.11

1.81

0.79–4.14

0.16

HR: hazard ratio; CI: confidence interval; BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; FBG: fasting blood glucose; HbA1c: serum glycated
hemoglobin; GGT: gamma-glutamyl transpeptidase.
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Table 3. Risk factors for carotid plaque occurrence (model 2).
Univariate analysis

Multivariate analysis

Variable

HR

95% CI

P-value HR

Age, years

1.00

0.96–1.04

0.90

0.98 0.94–1.03

95% CI

P-value
0.41

Men

0.97

0.46–2.03

0.94

0.78 0.35–1.71

0.53

BMI, kg/m2

1.08

0.96–1.21

0.22

Hypertension

0.75

0.10–5.50

0.78

Triglyceride, mg/dL

1.001

0.999–1.002 0.099

1.00 0.99–1.01

0.59

HDL, mg/dL

0.97

0.95–0.99

0.025

0.97 0.94–1.00

0.053

LDL, mg/dL

1.01

0.99–1.02

0.14

1.01 1.00–1.02

0.25

FBG, mg/dL

1.00

0.96–1.03

0.83

HbA1c, %

0.95

0.36–2.46

0.91

Nonfatty liver and GGT <50 U/L

1.00

Fatty liver and GGT <50 U/L

NA

NA

NA

NA

NA

NA

Nonfatty liver and GGT ≥50 U/L

1.69

0.81–3.55

0.16

1.56 0.69–3.54

0.29

Fatty liver and GGT ≥50 U/L

3.78

1.38–10.31

0.009

5.55 1.70–18.14 0.005

Never smoked

1.00

Past and current smoking

2.56

1.19–5.50

0.016

1.74 0.76–4.03

Drinking ≤20 g/day

1.00

Drinking >20, <60 g/day

1.09

0.26–4.62

0.90

Drinking ≥60 g/day

1.52

0.66–3.51

0.33

0.19

HR: hazard ratio; CI: confidence interval; BMI: body mass index; HDL: high-density lipoprotein;
LDL: low-density lipoprotein; FBG: fasting blood glucose; HbA1c: serum glycated hemoglobin;
GGT: gamma-glutamyl transpeptidase; NA: not available.

HDL cholesterol levels, past and current smoking, and
the combination of fatty liver and increased serum GGT
levels were significant factors according to our univariate
analysis. However, in the multivariate analysis, only the
combination of the two conditions remained significant.
Assessing these conditions may be useful for identifying
people at high risk for atherosclerotic plaque development
in apparently healthy populations.
The results of the current study are consistent with
those of a recent large-scale longitudinal study that investigated the causal relationship between NAFLD and
carotid atherosclerosis [8]. This recent study revealed that
persistent NAFLD is a significant risk factor for carotid
atherosclerosis, and that persistently high serum GGT
levels in people with NAFLD increase the risk of carotid
atherosclerosis development. Nevertheless, our study has
some advantages. First, the median follow-up period was
much longer in our study than that in the other study (13.3
years vs. 3.3 years). Second, the people who received medications capable of influencing the course of atherosclerosis
were excluded from our study. Thus, the impacts of fatty

liver and serum GGT levels on atherosclerosis progression
were more directly shown.
Our results suggest that not all fatty livers can exert a
promoting effect on plaque development. When dividing
people into four groups according to the presence or absence of fatty liver and serum GGT levels, people with both
fatty liver and a serum GGT level ≥50 U/L had the highest
incidence rates of carotid plaque occurrence. In contrast,
people with fatty liver and a serum GGT level <50 U/L did
not develop carotid plaques. Recent epidemiological studies have found that several factors, such as alcohol consumption, smoking, aging, and obesity can increase serum
GGT levels [20–23]. Regarding such factors, there were no
significant differences between people with fatty liver and
a serum GGT level ≥50 U/L and those with fatty liver and a
serum GGT level <50 U/L (data not shown). Other recent
studies have demonstrated that patients with advanced
fatty liver disease have high serum GGT levels [24]. We
speculate that our subjects with fatty liver and high serum
GGT levels may have advanced fatty liver disease. Future
studies will be required to test this hypothesis.
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The current study has some limitations. First, this study
had a small number of subjects, which may have reduced
its statistical power. Second, fatty liver was assessed by
routine US examinations. The low diagnostic accuracy in
assessing mild fatty liver with US may have affected the
study results [15]. However, recent US technologies have
improved accuracy for fatty liver diagnosis [25]. Future
studies should be performed with advanced technologies.
Third, this study included only Japanese subjects, which
may limit the generalizability of the study results.
In conclusion, our results demonstrate that the combination of fatty liver and increased serum GGT levels

increases the risk for atherosclerotic plaque development.
Assessing these two conditions can help identify people
who are at high risk of future CVD among apparently
healthy populations.
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